Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) — Neutral
RFL GlobeNewsWire — August 27, 2025NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 at the upcoming 15 th International Congress of Inborn Errors of Metabolism (ICIEM) being held September 2-6, 2025 in Kyoto, Japan.
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences — Neutral
RAPT GlobeNewsWire — August 27, 2025SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in September:
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences — Neutral
NAUT GlobeNewsWire — August 27, 2025SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences.
Protara Therapeutics to Participate in Upcoming Investor Conferences — Neutral
TARA GlobeNewsWire — August 27, 2025NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
Aclaris Therapeutics to Participate in Two September Healthcare Conferences — Neutral
ACRS GlobeNewsWire — August 27, 2025WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September. On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Cantor Global Healthcare Conference in New York, NY.
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference — Neutral
DSGN GlobeNewsWire — August 27, 2025CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York.
Soleno Therapeutics to Participate in Upcoming September Conferences — Neutral
SLNO GlobeNewsWire — August 27, 2025REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September:
Blade Air Mobility Sets Timing for Name Change to Strata Critical Medical and Commencement of Trading Under the New Ticker Symbol “SRTA” — Neutral
BLDE JOBY GlobeNewsWire — August 27, 2025NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), today confirmed that the previously announced change of its legal name to Strata Critical Medical, Inc is expected to occur this week. The change is intended to reflect the Company's plan to focus on providing mission critical logistics and medical services to hospitals and healthcare providers throughout the country following the closing of the previously announced agreement to sell Blade's Passenger business to Joby Aviation, Inc. (NYSE: JOBY).
Acronis and Intel Partner to Deliver Efficient, AI-Driven Threat Detection for Endpoint Devices — Neutral
INTC GlobeNewsWire — August 27, 2025SCHAFFHAUSEN, Switzerland, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Acronis, a global leader in cybersecurity and data protection, and Intel, today announced Acronis Cyber Protect Cloud's availability with AI PCs powered by Intel Core Ultra processors, a new collaboration that brings advanced and automated threat detection and remediation to endpoint devices without compromising performance. By integrating Acronis Cyber Protect Cloud with Intel technology, managed service providers (MSPs), managed security service providers (MSSPs), and enterprise customers experience faster, more efficient cybersecurity, ideal for today's resource-constrained users.
GD Culture Group Limited to Launch AI Immersive Reading Platform, Inviting Global Storytellers to Join — Neutral
GDC GlobeNewsWire — August 27, 2025NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- GD Culture Group Limited (“GDC” or the “Company”) (Nasdaq: GDC), and its subsidiary, AI Catalysis Corp. (“AI Catalysis”), today announced the upcoming launch of its AI Immersive Reading Platform (the “Platform”), an innovative ecosystem currently in its development and testing stage, designed to redefine how stories are created, shared, and enjoyed. This development marks a major milestone for the Company in interactive storytelling and opens the door for creators worldwide to participate in shaping a new future for digital narratives by joining its founding community.
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy — Neutral
VOR GlobeNewsWire — August 27, 2025Results reinforce telitacicept's potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with IgA nephropathy (IgAN).
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September — Neutral
IRD GlobeNewsWire — August 27, 2025RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it will present on its IRD gene therapy programs at the following scientific conferences in September 2025.
Annexon Biosciences to Participate in Upcoming September Investor Conferences — Neutral
ANNX GlobeNewsWire — August 27, 2025BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, Esq.
Septerna to Participate in Upcoming Investor Conferences — Neutral
SEPN GlobeNewsWire — August 27, 2025SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September:
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 — Neutral
GRCE GlobeNewsWire — August 27, 2025FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported by Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 PRINCETON, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that on August 22, 2025 the U.S. Food and Drug Administration …
Recursion to Participate in Upcoming Investor Conferences — Neutral
RXRX GlobeNewsWire — August 27, 2025Salt Lake City, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Citi 2025 BioPharma Back to School Conference — Wednesday, September 3, 2025 Morgan Stanley 23rd Annual Global Healthcare Conference — Monday, September 8, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives.
Cabaletta Bio to Participate in Upcoming Investor Conferences in September — Neutral
CABA GlobeNewsWire — August 27, 2025PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025: Webcasted fireside chat at 10:55 a.m. ET on Wednesday, September 3, 2025, in New York, NY.
Elutia to Participate in Upcoming Investor Conferences — Neutral
ELUT GlobeNewsWire — August 27, 2025GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York: Cantor Global Healthcare Conference Format: Fireside Chat and 1x1 Meetings Fireside Chat Date and Time: Thursday, September 4, 2025, 9:45 a.m.
MIMEDX to Participate in Upcoming Investor Conferences — Neutral
MDXG GlobeNewsWire — August 27, 2025MARIETTA, Ga., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
HeartFocus Launches First Clinical Product in the U.S. With Butterfly Network — Neutral
BFLY Business Wire — August 27, 2025BORDEAUX, France--(BUSINESS WIRE)--HeartFocus, the revolutionary, AI-enabled cardiac imaging software developed by data-driven medtech company DESKi, today announced its U.S. commercial launch. HeartFocus will initially be available on Butterfly Network's handheld ultrasound devices, the FDA-cleared software enables any healthcare professional to conduct diagnostic-quality heart ultrasounds after just hours of training. Health systems, primary care clinics, and clinical education institutions c.